News

Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali

Novo Nordisk (NYSE:NVO) has drawn investor attention after recent share price moves, with the stock showing a monthly gain alongside weaker past 3 months and 1 year total returns, prompting closer examination of its fundamentals. See our latest analysis for Novo Nordisk. The recent rebound, including a 14.9% 1 month share price return and a 9.6% 7 day share price return, comes after weaker longer term total shareholder returns. As a result, the momentum currently appears more like a short...

ZTS eyes a Q1 beat as companion animal products and international growth offset U.S. weakness ahead of its May 7 earnings report.

AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.